High prevalence of HIV-1 subtype G and natural polymorphisms at the protease gene among HIV-infected immigrants in Madrid

AIDS

Volumn 16, Issue 8, 2002, Pages 1163-1170

  Holguín, Africa ^a   Álvarez, Amparo ^a   Soriano, Vincent ^a,b  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b NONE   (Spain)

Author keywords

Drug resistance; Genetic variability; HIV subtypes; Protease

Indexed keywords

PROTEINASE; PROTEINASE INHIBITOR;

ADULT; ARTICLE; DRUG RESPONSE; FEMALE; GENETIC ANALYSIS; GENETIC MARKER; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMIGRANT; INFECTION RATE; MAJOR CLINICAL STUDY; MALE; NEGRO; NUCLEOTIDE SEQUENCE; PHYLOGENY; PRACTICE GUIDELINE; PRIORITY JOURNAL; SPAIN; TREATMENT PLANNING; VIRUS TYPING;

ADULT; AFRICA; EMIGRATION AND IMMIGRATION; ETHNIC GROUPS; FEMALE; GENE FREQUENCY; HIV INFECTIONS; HIV PROTEASE; HIV-1; HUMANS; MALE; POLYMORPHISM, GENETIC; SPAIN;

EID: 0037165905     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200205240-00010     Document Type: Article

References (59)

1. HIV population dynamic in vivo: Implications for genetic variation, pathogenesis, and therapy
2. Isolation and envelope sequence of a highly divergent HIV-1 isolate: Definition of a new HIV-1 group
3. Identification of a new HIV-1 distinct from group M and group O
4. HIV-1 nomenclature proposal
5. Unprecedented degree of HIV-1 group M genetic diversity in the Democratic Republic of Congo suggests that the HIV-1 pandemic originated in Central Africa
6. The puzzle of HIV-1 subtypes in Africa
7. Human immuno-deficiency viruses type 1 subtypes circulating in Spain
8. Protease gene analysis of HIV type 1 non-B subtypes in Spain
9. Recombinant HIV type 1 circulating in Spain
10. Prevalence of HIV-1 non-B subtypes in foreigners living in Madrid, Spain, and comparison of the performance of the Amplicor HIV-1 Monitor version 1.0 and the new automated version 1.5
11. HIV-1 genetic diversity in Galicia, Spain: BG intersubtype recombinant viruses circulating among injecting drug users
12. HIV-1 diversity in France, 1996-1998
13. High frequency of non-B subtypes in newly diagnosed HIV-1 infections in Switzerland
14. Large proportion of non-B subtypes and presence of zidovudine resistance mutations among Germans seroconvertors
15. Longstanding presence in Belgians of multiple non-B HIV-1 subtypes
16. Introduction of HIV-1 subtypes C, E and A into Austria
17. Presence of HIV type 1, group M, non-B subtypes, Bronx, New York: A sentinel site for monitoring HIV genetic diversity in the United States
18. National surveillance of HIV-1 subtypes for England and Wales
19. HIV-1/HIV-2 seronegativity in HIV-1 subtype O infected patients
20. Lack of screening test sensitivity during HIV-1 non-subtype B seroconversions
21. Polymerase chain reaction for diagnosis of HIV infection
22. Subtype-specific problems with quantification of plasma HIV-1 RNA
23. Comparison of three commercial methods for quantification of plasma viraemia in clinical specimens belonging to non-B subtypes
24. Erroneously low or undetectable plasma HIV-1 RNA load, determined by PCR, in West African and American patients with non-B subtype HIV-1 infection
25. Naturally occurring decreased susceptibility of HIV-1 subtype G to protease inhibitors
26. Sequence and drug susceptibility of subtype C reverse transcriptase from HIV-1 seroconverters in Zimbabwe
27. The neighbor-joining method: A new method for reconstructing phylogenetic trees
28. CLUSTAL W: Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice
29. Mutations in retroviral genes associated with drug resistance: 1999-2000 Update
30. Seroreactivity to HIV-1 V3 subtypes A to H peptides of Argentinian HIV-positive sera
31. Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease-naive individuals worldwide
32. Use of drug resistance sequence data for the systematic detection of non-B HIV-1 subtypes: How to create a sentinel site for monitoring the genetic diversity of HIV-1 at a country scale
33. HIV-1 genetic variability in Cameroon
34. Full genome sequences of human immunodeficiency virus type 1 subtypes G and G/A intersubtype recombinants
35. Prevalence of different HIV-1 subtypes in an urban clinic in Madrid
36. Increasing diversity of HIV-1 M serotypes in French blood donors over a 10-year period (1985-1995)
37. Dynamics of the HIV-1 subtype distribution in the Swedish HIV-1 epidemic during the period 1980-1993
38. Most HIV-1 genetic subtypes have entered Sweden
39. Multiple HIV-1 subtypes present among heterosexuals in Amsterdam 1988-1996: No evidence of spread of non-B-subtypes
40. HIV type 1 subtypes in the Netherlands circulating among women originating from AIDS-endemic regions
41. Diverse HIV-1 genetic subtypes in UK
42. Genetic subtypes of HIV type 1 in Hungary
43. Genetic evidence of multiple transmissions of HIV type 1 subtype F within Romania from adult blood donors to children
44. The subtypes of HIV type 1 in Greece
45. Genotypic characterization of HIV type 1 in Greece
46. Genetic diversity of env V3 loop sequences in HIV type 1 infected homosexuals, heterosexuals, intravenous drug users, and hemophilia patients in Norway: High prevalence of subtype B and detection of subtype C
47. HIV type 1 sequences in Romanian children and adults
48. Wide-spread circulation of a B/F intersubtype recombinant form among HIV-1-infected individuals in Buenos Aires, Argentina
49. Spread of distinct HIV type 1 AG recombinant lineages in Africa
50. Near full-length genome analysis of HIV type 1 CRF02-AG subtype C and CRF02-AG subtype G recombinants
51. Full genome sequences of HIV type 1 subtypes G and A/G intersubtypes recombinants
52. Subtype G and multiple forms of A/G intersubtype recombinant HIV type 1 in Nigeria
53. Genetic diversity of protease and reverse transcriptase sequences in non-B HIV type 1 strains: Evidence of many minor drug resistance mutations in treatment-naive patients
54. Analysis of HIV type 1 protease and reverse transcriptase in antiretroviral drug-naive Ugandan adults
55. Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV cohort study
56. Analysis of pol gene heterogeneity, viral quasispecies, and drug resistance in individuals infected with HIV-1 group O strains
57. Emergence of drug resistance mutations in HIV-2-infected subjects undergoing antiretroviral therapy